Posted by Dave Berry
Gate Way Group Contact: Deanna Hemphill
A coalition of health care providers, pharmaceutical companies, and patient organizations picked up momentum this week in an attempt to make Missouri the 28th state to require insurance coverage parity of both oral and intravenous cancer treatments. The American Legislative Exchange Council hosted members of the Missouri General Assembly, special guests, and other key stakeholders at the Capitol on Tuesday to discuss national trends in oral parity in chemotherapy medication, experiences in other states, and the relationship between innovation and access. Oklahoma Senator Greg Treat, Chair of the General Government Committee and Brian Rosen, Senior VP of Public Policy for the Leukemia & Lymphoma Society led much of the discussion.
The following day, the House Health Insurance Committee held an informational meeting to review recently released results from the actuarial study commissioned by the Missouri Legislature last year. The study was conducted by Lewis & Ellis of Overland Park, Kansas and concluded that requiring parity for oral anti-cancer medication would cost, on average, 57 cents a month for each insurance policyholder. The increase is said to be consistent with what is seen in other states that have passed parity legislation.
See below for the status of the three bills filed below:
- Senate Bill 663, filed by Senator Brian Munzlinger (R-Williamstown); Status: On the Senate Informal Calendar for Perfection (3/10/14)
- Senate Bill 668, filed by Senator Ryan Silvey (R-Kansas City); Status: Signed by the Governor
- House Bill 1327, filed by Representative Sheila Solon (R-Blue Springs); Status: Referred to Rules Committee (3/3/14)
News & Media:
Missouri Governor Signs Oral Chemotherapy Bill
Lawmakers give final approval to chemo parity bill
MISSOURI LEGISLATORS WEIGH COVERAGE OF ANTI-CANCER DRUGS (STL TODAY)
ORAL CHEMO PARITY LEGISLATION GEARING UP FOR 2014 (MISSOURI TIMES)